205 related articles for article (PubMed ID: 11668881)
1. Predictors of adherence to Copaxone therapy in individuals with relapsing-remitting multiple sclerosis.
Fraser C; Hadjimichael O; Vollmer T
J Neurosci Nurs; 2001 Oct; 33(5):231-9. PubMed ID: 11668881
[TBL] [Abstract][Full Text] [Related]
2. Predictors of adherence to glatiramer acetate therapy in individuals with self-reported progressive forms of multiple sclerosis.
Fraser C; Hadjimichael O; Vollmer T
J Neurosci Nurs; 2003 Jun; 35(3):163-70. PubMed ID: 12830664
[TBL] [Abstract][Full Text] [Related]
3. A prospective study of adherence to glatiramer acetate in individuals with multiple sclerosis.
Fraser C; Morgante L; Hadjimichael O; Vollmer T
J Neurosci Nurs; 2004 Jun; 36(3):120-9. PubMed ID: 15233411
[TBL] [Abstract][Full Text] [Related]
4. Comparison of glatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up.
Flechter S; Vardi J; Pollak L; Rabey JM
J Neurol Sci; 2002 May; 197(1-2):51-5. PubMed ID: 11997066
[TBL] [Abstract][Full Text] [Related]
5. A multicenter study of the predictors of adherence to self-injected glatiramer acetate for treatment of relapsing-remitting multiple sclerosis.
Zwibel H; Pardo G; Smith S; Denney D; Oleen-Burkey M
J Neurol; 2011 Mar; 258(3):402-11. PubMed ID: 20922405
[TBL] [Abstract][Full Text] [Related]
6. Higher satisfaction and adherence with glatiramer acetate 40 mg/mL TIW vs 20 mg/mL QD in RRMS.
Cutter G; Veneziano A; Grinspan A; Al-Banna M; Boyko A; Zakharova M; Maida E; Pasic MB; Gandhi SK; Everts R; Cordioli C; Rossi S
Mult Scler Relat Disord; 2019 Aug; 33():13-21. PubMed ID: 31132664
[TBL] [Abstract][Full Text] [Related]
7. Assessing the role of patient support services on adherence rates in patients using glatiramer acetate for relapsing-remitting multiple sclerosis.
Jones JL; Scheidt DJ; Kaushal RS; Carroll CA
J Med Econ; 2013; 16(2):213-20. PubMed ID: 23098539
[TBL] [Abstract][Full Text] [Related]
8. Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis.
Soós N; Shakery K; Mrowietz U
Am J Clin Dermatol; 2004; 5(5):357-9. PubMed ID: 15554737
[TBL] [Abstract][Full Text] [Related]
9. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group.
Johnson KP; Brooks BR; Ford CC; Goodman A; Guarnaccia J; Lisak RP; Myers LW; Panitch HS; Pruitt A; Rose JW; Kachuck N; Wolinsky JS
Mult Scler; 2000 Aug; 6(4):255-66. PubMed ID: 10962546
[TBL] [Abstract][Full Text] [Related]
10. Effect of oral antihistamine on local injection site reactions with self-administered glatiramer acetate.
Pardo G; Boutwell C; Conner J; Denney D; Oleen-Burkey M
J Neurosci Nurs; 2010 Feb; 42(1):40-6. PubMed ID: 20187348
[TBL] [Abstract][Full Text] [Related]
11. [Glatiramer acetate (Copaxone) influence on different stages of multiple sclerosis pathogenesis].
Shmidt TE; Zhuchenko TD; Iakhno NN
Zh Nevrol Psikhiatr Im S S Korsakova; 2003; (Spec No 2):79-82. PubMed ID: 12938640
[TBL] [Abstract][Full Text] [Related]
12. [Use of glatiramer acetate (Copaxone) in the treatment of patients with multiple sclerosis. Experience of the Moscow multiple sclerosis center].
Demina TL; Davydovskaia MV; Lashch NIu; Popova NF; Khachanova NV; Zhuchenko TD
Zh Nevrol Psikhiatr Im S S Korsakova; 2003; (Spec No 2):91-7. PubMed ID: 12938642
[TBL] [Abstract][Full Text] [Related]
13. [Comparative, placebo-controlled clinical study of efficacy and safety of glatiramer acetate 20 mg in patients with relapsing-remitting multiple sclerosis: results of the first year of the study].
Boyko AN; Lashch NY; Sharanova SN; Zakharova MN; Trifonova OV; Simaniv TO; Lysogorskaya EV; Guryanova OE; Kotov SV; Iakushina TI; Lizhdvoy VY; Belova YA; Khabirov FA; Babicheva NN; Khaibullin TI; Granatov EV; Averyanova LA; Sazonov DV; Odinak MM; Trinitatsky YV; Tsukurova LA; Sergeeva AI; Ivanov RA; Shustova MS
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(10 Pt 2):61-67. PubMed ID: 28139613
[TBL] [Abstract][Full Text] [Related]
14. Therapy with glatiramer acetate for multiple sclerosis.
Munari L; Lovati R; Boiko A
Cochrane Database Syst Rev; 2004; (1):CD004678. PubMed ID: 14974077
[TBL] [Abstract][Full Text] [Related]
15. Glatiramer acetate treatment persistence - but not adherence - in multiple sclerosis patients is predicted by health-related quality of life and self-efficacy: a prospective web-based patient-centred study (CAIR study).
Jongen PJ; Lemmens WA; Hoogervorst EL; Donders R
Health Qual Life Outcomes; 2017 Mar; 15(1):50. PubMed ID: 28292329
[TBL] [Abstract][Full Text] [Related]
16. Glatiramer acetate for the treatment of multiple sclerosis.
Wolinsky JS
Expert Opin Pharmacother; 2004 Apr; 5(4):875-91. PubMed ID: 15102570
[TBL] [Abstract][Full Text] [Related]
17. Glatiramer acetate for multiple sclerosis.
La Mantia L; Munari LM; Lovati R
Cochrane Database Syst Rev; 2010 May; (5):CD004678. PubMed ID: 20464733
[TBL] [Abstract][Full Text] [Related]
18. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis.
Río J; Porcel J; Téllez N; Sánchez-Betancourt A; Tintoré M; Arévalo MJ; Nos C; Montalban X
Mult Scler; 2005 Jun; 11(3):306-9. PubMed ID: 15957512
[TBL] [Abstract][Full Text] [Related]
19. Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial.
Johnson KP; Brooks BR; Ford CC; Goodman AD; Lisak RP; Myers LW; Pruitt AA; Rizzo MA; Rose JW; Weiner LP; Wolinsky JS
Mult Scler; 2003 Dec; 9(6):585-91. PubMed ID: 14664471
[TBL] [Abstract][Full Text] [Related]
20. [Results of open post-registration clinical trials of copaxone in patients with multiple sclerosis].
Zavalishin IA; Gusev EI; Iakhno NN; Ronkin MA; Shmidt TE; Demina TL; Kugoev AI; Adarcheva LS; Niiazbekova AS; Zakharova MN; Peresedova AB; Toropina GG; Klishevskaia LA; Maksimenko IM; Krotenkova MV; Konovalov SN; Rebrova OIu; Zhuchenko TD
Zh Nevrol Psikhiatr Im S S Korsakova; 2002; Suppl():59-64. PubMed ID: 12418394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
